A Randomised, Double-Blind, Placebo-Controlled, 3-Period Cross-Over Study to Evaluate the Effect of Two Doses of GSK2190915 on the Allergen-Induced Early Asthmatic Response in Subjects With Mild Asthma.

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, 3-Period Cross-Over Study to Evaluate the Effect of Two Doses of GSK2190915 on the Allergen-Induced Early Asthmatic Response in Subjects With Mild Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Fiboflapon (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Aug 2009 Actual patient number (17) added as reported by ClinicalTrials.gov.
    • 08 Aug 2009 Actual end date (1 Jul 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top